Hertzel C Gerstein Selected Research

Incretins

1/2023	Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis.
11/2020	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
1/2020	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
1/2020	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
1/2018	Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hertzel C Gerstein Research Topics

Disease

107	Type 2 Diabetes Mellitus (MODY) 05/2024 - 03/2002
40	Cardiovascular Diseases (Cardiovascular Disease) 12/2023 - 01/2002
29	Heart Failure 12/2023 - 03/2003
25	Glucose Intolerance 11/2023 - 02/2003
24	Myocardial Infarction 04/2023 - 09/2002
23	Stroke (Strokes) 04/2023 - 09/2002
17	Insulin Resistance 07/2023 - 01/2002
14	Hypoglycemia (Reactive Hypoglycemia) 01/2019 - 07/2005
12	Cognitive Dysfunction 01/2024 - 10/2013
9	Obesity 11/2023 - 06/2008
9	Hypertension (High Blood Pressure) 02/2023 - 01/2002
9	Acute Coronary Syndrome 01/2023 - 11/2008
8	Neoplasms (Cancer) 05/2024 - 12/2007
8	Renal Insufficiency (Renal Failure) 01/2023 - 01/2002
7	Diabetes Mellitus 01/2023 - 07/2005
6	Kidney Diseases (Kidney Disease) 12/2023 - 05/2009
6	Atherosclerosis 10/2022 - 12/2008
6	Body Weight (Weight, Body) 01/2022 - 02/2007
6	Dyslipidemias (Dyslipidemia) 01/2020 - 01/2003
6	Weight Gain 10/2018 - 02/2007
5	Vascular Diseases (Vascular Disease) 03/2024 - 03/2003
5	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/2023 - 07/2005
5	Albuminuria 02/2023 - 03/2003
5	Unstable Angina 01/2023 - 12/2015
5	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2021 - 07/2010
5	Proteinuria 06/2010 - 03/2003
4	Dementia (Dementias) 05/2024 - 01/2014
4	Coronary Disease (Coronary Heart Disease) 11/2023 - 11/2017
4	Weight Loss (Weight Reduction) 07/2023 - 08/2013
4	Chronic Renal Insufficiency 01/2022 - 12/2017
4	Hyperglycemia 12/2021 - 11/2007
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2015 - 01/2011
3	Prediabetic State (Prediabetes) 05/2024 - 07/2015
3	Hypotension (Low Blood Pressure) 01/2023 - 02/2013
3	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022 - 02/2013
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 12/2008
3	Inflammation (Inflammations) 01/2019 - 01/2007
3	Hyperkalemia 02/2013 - 01/2002
2	Peripheral Arterial Disease 05/2024 - 01/2019
2	Overweight 11/2023 - 11/2014
2	Non-alcoholic Fatty Liver Disease 07/2023 - 05/2015
2	Gestational Diabetes (Gestational Diabetes Mellitus) 01/2023 - 01/2022
2	Pancreatic Neoplasms (Pancreatic Cancer) 10/2021 - 12/2015
2	Pancreatitis 10/2021 - 12/2015

Drug/Important Bio-Agent (IBA)

65	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 03/2002
41	Insulin (Novolin)FDA Link 01/2024 - 03/2005
30	Insulin Glargine (Lantus)FDA Link 05/2024 - 11/2007
14	CreatinineIBA 01/2022 - 01/2002
13	LipidsIBA 12/2023 - 01/2007
13	dulaglutideIBA 01/2023 - 01/2018
12	Metformin (Glucophage)FDA LinkGeneric 11/2023 - 07/2010
12	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 02/2023 - 03/2002
11	Ramipril (Altace)FDA LinkGeneric 07/2015 - 01/2002
10	Glucagon-Like Peptide-1 ReceptorIBA 02/2023 - 01/2019
10	Rosiglitazone (Avandia)FDA Link 03/2011 - 10/2006
8	Biomarkers (Surrogate Marker)IBA 05/2024 - 12/2015
8	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2024 - 07/2012
8	omega-Chloroacetophenone (Mace)IBA 12/2023 - 11/2020
8	lixisenatideIBA 11/2023 - 05/2015
7	efpeglenatideIBA 12/2023 - 01/2021
7	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2023 - 06/2007
7	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2021 - 01/2018
7	Nicotine FDA Link 09/2012 - 06/2007
5	IncretinsIBA 01/2023 - 01/2018
5	AlbuminsIBA 01/2022 - 12/2006
5	2,4-thiazolidinedione (thiazolidinedione)IBA 10/2010 - 12/2008
4	Acarbose FDA LinkGeneric 11/2023 - 01/2017
4	Natriuretic PeptidesIBA 01/2023 - 05/2017
4	HDL CholesterolIBA 01/2023 - 11/2014
4	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2021
4	Fibric Acids (Fibrates)IBA 01/2020 - 06/2007
4	Fenofibrate (CiL)FDA LinkGeneric 01/2020 - 04/2010
4	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019 - 03/2002
4	Blood Glucose (Blood Sugar)IBA 01/2018 - 07/2010
4	hydroxide ionIBA 04/2014 - 06/2010
4	Vitamin D FDA LinkGeneric 04/2014 - 06/2010
4	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 02/2013 - 01/2002
4	candesartanIBA 08/2009 - 07/2005
3	Retinaldehyde (Retinal)IBA 05/2024 - 01/2017
3	Proteins (Proteins, Gene)FDA Link 05/2024 - 01/2022
3	Testosterone (Sustanon)FDA Link 12/2023 - 01/2019
3	Triglycerides (Triacylglycerol)IBA 01/2017 - 11/2014
3	ThiazolidinedionesIBA 10/2010 - 03/2010
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2023 - 05/2015
2	Sex Hormone-Binding GlobulinIBA 12/2023 - 01/2019
2	CholesterolIBA 01/2023 - 01/2023
2	Sodium-Glucose Transporter 2 InhibitorsIBA 12/2022 - 01/2022
2	SodiumIBA 07/2022 - 01/2022
2	LDL CholesterolIBA 01/2022 - 03/2014
2	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 05/2017
2	Advanced Glycation End ProductsIBA 01/2022 - 01/2022
2	Thyroid HormonesIBA 01/2021 - 08/2004
2	C-PeptideIBA 01/2020 - 03/2010

Therapy/Procedure

42	Therapeutics 12/2023 - 08/2004
21	Glycemic Control 01/2022 - 03/2002
4	Injections 01/2022 - 07/2005
4	Subcutaneous Injections 01/2021 - 01/2018
2	Surgical Amputation (Amputations) 03/2024 - 08/2011
2	Renal Replacement Therapy (Therapies, Renal Replacement) 10/2021 - 01/2020
2	Secondary Prevention 01/2021 - 11/2017